CARDIAC Publication-derived

Cardiac Cell Therapy with Immune Tolerance

Source Deuse et al. · Department of Surgery, University of California San Francisco, San Francisco, USA · 10.1038/s41587-019-0016-3

👤 Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Yazawa M, Bhatt S, Bhatt DL, Bhatt AB, Schrepfer S ⏱ 16800 min 🧫 iPSC-Derived (Human iPSCs — CRISPR B2M/CIITA Knockout + CD47 Knock-In)

Abstract

Deuse et al. engineered hypoimmunogenic iPSC-CMs via triple CRISPR editing (B2M-KO, CIITA-KO, CD47-KI) that evade T-cell, NK cell, and macrophage killing. These universal donor cells survive allogeneic transplantation without immunosuppression in humanized mice, enabling off-the-shelf cardiac cell therapy products.

Cell source

iPSC-Derived (Human iPSCs — CRISPR B2M/CIITA Knockout + CD47 Knock-In)

Application

Universal Donor Cell Therapy

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Deuse et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence